Metastatic Presentation and Outcomes in Pancreatic Ductal Adenocarcinoma

Epidemiology of Metastatic Disease at Diagnosis

Approximately 50‑60 % of patients present with distant metastatic (Stage IV) pancreatic ductal adenocarcinoma, making it the cancer with the highest rate of metastatic presentation among common malignancies. Evidence level not specified. 1, 2
Only 9‑20 % of patients are diagnosed with disease confined to the pancreas (localized stage). Evidence level not specified. 3, 4

The American College of Radiology notes that 80‑85 % of patients present with advanced disease that is not amenable to surgical resection, underscoring the predominance of locally advanced or metastatic disease at presentation. Evidence level not specified. 3, 4
The European Society for Medical Oncology (ESMO) emphasizes that >95 % of patients die of pancreatic cancer because of the very high incidence of metastatic disease at diagnosis. Evidence level not specified. 7, 8

Metastatic involvement of the lungs/respiratory tract occurs in 3.5‑16 % of cases, with the range reflecting differences in detection methods. Evidence level not specified. 5, 6

For patients with distant (Stage IV) disease at diagnosis, the 1‑year survival is ~15 % and the 5‑year survival drops to ~2 %. Evidence level not specified. 3
Patients with localized disease have a 5‑year survival of ~26 %. Evidence level not specified. 3
The overall 5‑year survival across all stages of pancreatic ductal adenocarcinoma is less than 5 %. Evidence level not specified. 1, 2

Among the minority who undergo curative‑intent pancreatic resection, 80‑85 % develop disease recurrence, most commonly as early liver metastasis. Evidence level not specified. 5, 6

The extraordinarily high metastatic rate at presentation (50‑60 %) is a key reason why screening for pancreatic cancer is not recommended for the general population. Evidence level not specified. 3, 7, 9
Accurate staging with multiphasic CT imaging is essential to detect distant metastases and to avoid non‑beneficial, potentially morbid surgeries in patients unlikely to benefit from resection. Evidence level not specified. 3, 5